A method for inhibiting staphyloxanthin synthesis and its application

By using eugenol to inhibit staphylococci flavin synthesis, the drug resistance and pathogenicity of Staphylococcus aureus are solved, and new antibacterial strategies are provided, with wide application potential.

CN114164150BActive Publication Date: 2024-11-26SHANGHAI JIAOTONG UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202111442761.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-11-30
Publication Date
2024-11-26
Estimated Expiration
2041-11-30

AI Technical Summary

Technical Problem

The multidrug resistance of Staphylococcus aureus leads to the failure of traditional antibiotics, and the development of new antibiotics is difficult, and the existing technology is difficult to effectively inhibit the synthesis of staphylococcus flavin, making it difficult to control infection.

Method used

Eugenol is used as an antibacterial agent, and by inhibiting the synthesis of staphylococcal flavin, dimethyl sulfoxide is used as a solvent to prepare eugenol solutions of different concentrations and co-culture with Staphylococcus aureus to detect its antibacterial and inhibit Staphylococcus yellow. The effect of the quasi-shaped.

Benefits of technology

Without affecting the viability of Staphylococcus aureus, it effectively inhibits its staphylococcal flavin synthesis, alleviates the development of drug resistance and pathogenic problems, and provides new prevention and control ideas for the fields of food, drugs and human health.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114164150B_ABST
    Figure CN114164150B_ABST
Patent Text Reader

Abstract

The invention discloses a method for inhibiting the synthesis of staphyloxanthin and an application thereof, and relates to the field of microbial antimicrobial agents. According to the fact that eugenol can inhibit the synthesis of staphyloxanthin of methicillin-sensitive (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA), and the minimum inhibition concentration is 300 μg / mL, which is significantly lower than the minimum inhibitory concentration (MIC) (800-1000 μg / mL), the invention proposes that eugenol can inhibit the synthesis of staphyloxanthin without affecting the viability of Staphylococcus aureus, provides a method for effectively alleviating and solving the problems of drug resistance development and pathogenicity of Staphylococcus aureus, proposes a new idea for preventing and controlling Staphylococcus aureus, and has important practical significance.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of microbial antibacterial agents, and in particular to a eugenol antibacterial agent and application thereof. Background Art

[0002] Since 1980, the number of cases of foodborne diseases has continued to increase worldwide, and the prevention, control and treatment of foodborne diseases has become one of the urgent problems to be overcome in the field of public health around the world. The results of the World Health Organization (WHO) global antibiotic monitoring show that antibiotic resistance is common among 500,000 patients with suspected bacterial infections in 22 countries. The Chinese antibiotic resistance monitoring report shows that among Gram-positive pathogens, Staphylococcus aureus (S. aureus) and methicillin-resistant Staphylococcus aureus (MRSA) strains have the highest infection rates. Among them, the rapid emergence, spread and prevalence of multidrug-resistant Staphylococcus aureus, especially MRSA, have made most antibiotics ineffective. In addition, the development of new antibiotics is extremely difficult and often requires a long process. The number of people who are sick due to infection with Staphylococcus aureus continues to increase.

[0003] Currently, the "indirect killing" strategy that focuses on utilizing the host immune system can weaken the pathogenicity of bacteria without directly affecting their viability, thereby significantly slowing the development of drug resistance. The anti-virulence strategy is one of the "indirect" antibacterial means that can intervene, regulate or destroy the virulence of microorganisms without directly killing them, providing a new option for combating pathogenic bacteria.

[0004] Chinese herbal medicine is a unique natural medicine obtained through exploration and practice by human beings for thousands of years. It has the characteristics of wide resources, low cost, stable effect, low toxicity and side effects, not easy to develop drug resistance and can fully regulate body functions. Therefore, the active ingredients of Chinese herbal medicine are an important resource library for the development of alternative drugs to antibiotics. Clove is a plant of the genus Syzygium in the Myrtaceae family. Phenols represented by eugenol are important active ingredients of clove. Studies have shown that eugenol has antibacterial and antiviral effects, and can also be used as a soap and oral spice. However, there has been no report that eugenol can inhibit the synthesis of staphyloxanthin without affecting the viability of Staphylococcus aureus.

[0005] In view of the above facts, those skilled in the art are committed to going beyond the traditional antibiotic treatment strategy, discovering active ingredients that can inhibit the synthesis of staphyloxanthin, and developing antibacterial agents with new mechanisms of action to solve the problem of treating Staphylococcus aureus infections. Summary of the invention

[0006] To achieve the above purpose, the present invention adopts the following technical solutions:

[0007] The first object of the present invention is to provide a method for inhibiting the synthesis of staphyloxanthin, comprising the following steps:

[0008] Step 1: Dip the frozen starting strain for amplification culture, resuspend the bacteria with physiological saline, adjust the OD value of the bacterial solution to 0.1, and then dilute the bacterial solution with TSB medium;

[0009] Step 2, preparing eugenol solution;

[0010] Step 3, mixing the eugenol solution into the bacterial solution of step 1 for co-cultivation;

[0011] Step 4: Detect the OD value of the bacterial solution after co-cultivation.

[0012] Preferably, the bacterial solution is diluted 1000 times using TSB medium.

[0013] Preferably, the physiological saline is 1 mL of 0.85% physiological saline.

[0014] Preferably, step 2 comprises using dimethyl sulfoxide as a solvent to prepare a 100 mg / mL eugenol mother solution, and then diluting it to different concentrations.

[0015] Preferably, the co-cultivation time is 24 h.

[0016] The second object of the present invention is to provide a eugenol antibacterial agent prepared by a method of inhibiting the synthesis of staphyloxanthin, which comprises dimethyl sulfoxide and eugenol, wherein the dimethyl sulfoxide is a solvent.

[0017] In one embodiment, the minimum inhibitory concentration (MIC) of eugenol is 800-1000 μg / mL.

[0018] In one embodiment, the minimum inhibitory concentration (MSIC) of eugenol on staphyloxanthin is 300 μg / mL.

[0019] The third object of the present invention is to provide an application of a eugenol antibacterial agent in inhibiting the synthesis of Staphylococcus aureus xanthin.

[0020] Furthermore, the Staphylococcus aureus is a standard strain of methicillin-sensitive (MSSA), methicillin-resistant Staphylococcus aureus (MRSA) and a food-derived strain.

[0021] Beneficial effects:

[0022] The present invention provides a method for inhibiting the synthesis of staphyloxanthin and its application. The method uses eugenol, an effective ingredient of Chinese herbal medicine, to inhibit the synthesis of staphyloxanthin without affecting the viability of Staphylococcus aureus. The anti-toxicity strategy adopted by the method is expected to alleviate and solve the drug resistance development and pathogenicity problems of Staphylococcus aureus, and puts forward new ideas for the prevention and control of Staphylococcus aureus. It has wide application potential in the fields of food, medicine and human health.

[0023] The concept and technical effects of the present invention will be further described below in conjunction with the accompanying drawings to fully understand the purpose, features and effects of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] In the accompanying drawings of the present invention, Figure 1 and Figure 2 The markers represent: (A) S. aureus ATCC 43300 (B) S. aureus SJTUF 21656 (C) S. aureus ATCC 29213 (D) S. aureus SJTUF 21660; Figure 3 The markers represent: (A) S. aureus ATCC 29213 (B) S. aureus ATCC 43300 (C) S. aureus Newman (D) S. aureus CrtN gene knockout strain and complemented strain;

[0025] Figure 1 It is the growth curve of different starting bacterial liquids under the action of eugenol;

[0026] Figure 2 The inhibitory effect of eugenol on flavin in different bacterial cultures

[0027] Figure 3 Raman spectra images of flavin extracts under different treatment conditions. DETAILED DESCRIPTION

[0028] The following describes several preferred embodiments of the present invention with reference to the drawings in the specification, so that the technical content is clearer and easier to understand. The present invention can be embodied in many different forms of embodiments, and the protection scope of the present invention is not limited to the embodiments mentioned in the text.

[0029] Example 1: Determination of the growth curve of Staphylococcus aureus under the action of eugenol.

[0030] Using MRSA standard strain ATCC 43300, food source strain SJTUF 21656 and MSSA standard strain ATCC29213, food source strain SJTUF 21660 as starting strains, a series of eugenol treatment groups with concentration gradients were set up to explore their effects on the viability of Staphylococcus aureus.

[0031] First, the bacterial solution frozen at -80°C was dipped and inoculated onto Baird-Parker (BP) medium, and then placed in a constant temperature and humidity incubator at 37°C for 24 hours.

[0032] A single colony on the culture medium was picked up and placed into tryptone broth (TSB), and cultured in a shaker at 37°C and 180 rpm for 6 h.

[0033] Pipette 1 mL of the above bacterial solution into a 1.5 mL centrifuge tube, centrifuge at 6000 r / min for 3 min, remove the supernatant and add 0.85% saline to wash the bacteria, mix well and centrifuge again (6000 r / min, 3 min), repeat 3 times.

[0034] Add 1 mL of 0.85% saline to resuspend the bacteria, adjust the OD value of the bacterial solution to 0.1, and then dilute it 1000 times with TSB medium for later use.

[0035] Using dimethyl sulfoxide (DMSO) as solvent, a 100 mg / mL eugenol stock solution was prepared and diluted to 90 / 80 / 70 / 60 / 50 / 40 / 30 / 20 / 10 mg / mL respectively.

[0036] To ensure that the DMSO content in the culture system does not exceed 1%, 297 μL of the above bacterial solution and 3 μL of the above eugenol solutions of various concentrations were added to each well of the growth curve plate, and the edges were sealed with 0.85% saline. The growth curve of Staphylococcus aureus under the action of eugenol was measured using a growth curve instrument (37°C, 24h, OD value was tested every 30min). The experimental results are shown in the figure. Figure 1 As shown, the minimum inhibitory concentrations of eugenol against MRSA standard strain ATCC 43300 and food source strain SJTUF21656 and MSSA standard strain ATCC 29213 and food source strain SJTUF 21660 were 1000 μg / mL, 800 μg / mL, 1000 μg / mL and 900 μg / mL, respectively.

[0037] Example 2: Test on the inhibitory effect of eugenol on the synthesis of eugenol in Staphylococcus aureus.

[0038] A single colony on the BP medium was picked up and placed in a PA bottle with 10 mL of TSB, and cultured in a shaking incubator at 37°C and 180 rpm for 4 h.

[0039] Use DMSO to prepare a 50 mg / mL eugenol stock solution, and dilute it to 10 / 20 / 30 / 40 mg / mL, respectively. Then pipette 300 μL of each concentration of eugenol solution into 30 mL of TSB, mix well, inoculate 300 μL of activated bacterial solution, and culture in a shaker at 37°C and 180 r / min for 24 h.

[0040] After 24 hours of co-culture, the bacterial solution was transferred to a 50 mL centrifuge tube and centrifuged (8000 r / min, 5 min). After removing the supernatant, 0.85% saline was added to wash the bacteria, mixed and centrifuged again (8000 r / min, 5 min), and repeated 3 times.

[0041] Add 5 mL of methanol to the bacterial pellet, mix well by blowing, and place in a constant temperature water bath at 55°C in the dark for 3 h to complete the extraction of staphyloxanthin. Carvacrol (final concentration of 80 μg / mL) was used as the positive control of this experiment.

[0042] Pipette 1 mL of supernatant into a 1.5 mL centrifuge tube, centrifuge (12000 r / min, 3 min), take 200 μL of supernatant into a 96-well plate, and test the OD462nm value. Figure 2 As shown, the minimum inhibitory staphyloxanthin concentration (MSIC) of eugenol against four strains of Staphylococcus aureus was 300 μg / mL.

[0043] To further prove that eugenol has an effect on the synthesis of staphyloxanthin, the Raman spectra of staphylococcal flavin produced by Staphylococcus aureus treated with 1 / 2MSIC, MSIC, and 2MSIC eugenol were measured using a dispersive confocal Raman spectrometer, and the CrtN gene knockout strain and CrtN gene complementation strain of S. aureus Newman were used as controls. The extraction method of staphyloxanthin was the same as that of Examples 1 and 2, i.e., the methanol extraction method. The experimental results are shown in Figure 2. Figure 3 As shown:

[0044] Staphyloxanthin at 1008 cm -1 (methyl vibration), 1161cm -1 (CC expansion) and 1525cm -1 There are three characteristic Raman peaks near (C=C stretching). As the amount of staphyloxanthin synthesis decreases, 1161cm -1 and 1525cm -1 The intensity of the Raman peak at 240° gradually decreases, which is related to the presence of a large number of CC and C=C in the structure of staphyloxanthin.

[0045] CrtN is a key enzyme in the synthesis pathway of staphyloxanthin. Staphylococcus aureus with a CrtN gene deletion cannot synthesize staphyloxanthin normally. Therefore, the Raman spectra of flavin extracted from the culture of CrtN gene knockout strain and CrtN gene complement strain just confirmed that the 1161cm -1 (CC expansion) and 1525cm -1 The intensity of the Raman peak at (C=C stretching) is positively correlated with the synthesis amount of staphyloxanthin.

[0046] In summary, based on the above experimental results, the present invention provides a new approach for preventing and controlling Staphylococcus aureus, and has broad application potential in the fields of food, medicine and human health.

[0047] The preferred specific embodiments of the present invention are described in detail above. It should be understood that ordinary technicians in the field can make many modifications and changes based on the concept of the present invention without creative work. Therefore, all technical solutions that can be obtained by technicians in the technical field based on the concept of the present invention through logical analysis, reasoning or limited experiments on the basis of the prior art should be within the scope of protection determined by the claims.

Claims

1. A method for inhibiting the synthesis of staphyloxanthin, characterized in that: The following steps are involved: Step 1, dipping the frozen starting strain for amplification culture, resuspending the bacteria with physiological saline, adjusting the OD value of the bacterial solution to 0.1, and then diluting the bacterial solution with TSB medium; the Staphylococcus aureus strain is: MRSA standard strain ATCC 43300 and / or MSSA standard strain ATCC 29213; Step 2, preparing a eugenol solution; the concentration of the eugenol solution is 300 μg / mL; Step 3, mixing the eugenol solution into the bacterial solution of step 1 for co-cultivation; Step 4: Detect the OD value of the bacterial solution after co-cultivation.

2. The method for inhibiting staphyloxanthin synthesis according to claim 1, characterized in that: In step 1, the bacterial solution was diluted 1000 times using TSB medium.

3. The method for inhibiting staphyloxanthin synthesis according to claim 1, characterized in that: In step 1, the physiological saline is 1 mL of 0.85% physiological saline.

4. The method for inhibiting staphyloxanthin synthesis according to claim 1, characterized in that: Step 2 comprises using dimethyl sulfoxide as a solvent to prepare a 100 mg / mL eugenol stock solution, and then diluting it to different concentrations.

5. The method for inhibiting staphyloxanthin synthesis according to claim 1, characterized in that: The co-culture time in step 3 is 24 h.

6. A eugenol antibacterial agent prepared by the method for inhibiting the synthesis of staphyloxanthin according to claim 1 or 4, characterized in that: The invention comprises dimethyl sulfoxide and eugenol, wherein the dimethyl sulfoxide is a solvent; the minimum inhibitory concentration (MIC) of the eugenol is 800-1000 μg / mL; the staphylococcus strain is: MRSA standard strain ATCC 43300 and / or MSSA standard strain ATCC 29213; and the concentration of the eugenol solution is 300 μg / mL.

7. Use of the eugenol antibacterial agent according to claim 6 in the preparation of an antibacterial agent for inhibiting the synthesis of staphyloxanthin in Staphylococcus aureus without affecting its viability; the Staphylococcus aureus strain is: MRSA standard strain ATCC43300 and / or MSSA standard strain ATCC 29213; the concentration of the eugenol solution is 300 μg / mL.

Citation Information

Patent Citations

  • Application of eugenol / clove oil in inhibiting oral opportunistic pathogens

    CN107334755A

  • METHOD AND DEVICE FOR ANNIHILATION OF Staphylococcus aureus

    US20200306295A1

  • Use of NRF2 activators for the treatment of staphylococcus aureus infections

    WO2020094767A1